Current trends in drug therapy for resectable locally advanced gastric cancer

Titov K.S., Andreytsev I.L., Grekov D.N., Kuzmenko A.A., Lebedev S.S., Podzolkova N.M., Chekini A.K., Sokolov N.Yu., Minenkova A.G.

1) S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russia; 2) People’s Friendship University of Russia (RUDN University), Moscow, Russia; 3) Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Gastric cancer is one of the most pressing problems in modern oncology. Surgery is currently the main treatment for resectable gastric cancer, but overall survival rates remain unsatisfactory. To date, combination therapy is the standard approach. Modern drug therapy, in addition to chemotherapy, includes targeted and immunotherapy, and it has changed significantly over the past few years. At the same time, perioperative chemotherapy regimens differ. In recent years, perioperative therapy using new agents such as targeted drugs and immune checkpoint inhibitors (ICIs) has also been investigated with promising results. Perioperative therapy has become an integral part of treatment strategies and requires further study. This review demonstrates modern perioperative therapy regimens, their recent achievements and presents future prospects.

Keywords

About the Authors

Konstantin S. Titov, Dr. Sci. (Med.), Professor, Leading Researcher, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Professor, Department of Oncology and Roentgenology named after Academician V.P. Kharchenko, Medical Institute, People’s Friendship University of Russia (RUDN University), Moscow, Russia; ks-titov@mail.ru, ОRCID iD: https://orcid.org/0000-0003-4460-9136, SPIN-code: 7795-6512, AuthorID: 921470 (corresponding author)
Igor L. Andreytsev, Dr. Sci. (Med.), Leading Researcher, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russia; ОRCID iD: https://orcid.org/0000-0002-6756-9555
Dmitry N. Grekov, Cand. Sci. (Med.), Associate Professor, Chief Physician, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Associate Professor, Department of Surgery, Faculty of Surgery, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ORCID iD: https://orcid.org/0000-0001-8391-1210, SPIN-code: 6841-7128, AuthorID: 989579
Aleksandr A. Kuzmenko, Surgeon, Oncosurgical Department No. 72, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russia; ORCID iD: https://orcid.org/0000-0002-1488-7795
Sergey S. Lebedev, Dr. Sci. (Med.), Associate Professor, Deputy Chief Physician for Oncology, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Professor, Department of Surgery, Faculty of Surgery, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ORCID iD: https://orcid.org/0000-0001-5366-1281
Natalia M. Podzolkova, Dr. Sci. (Med.), Professor, Head of the Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ORCID: https://orcid.org/0000-0001-9183-7030
Antonio K. Chekini, Cand.Sci. (Med.), Senior Researcher, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russia; ORCID iD: https://orcid.org/0000-0001-9065-4726, SPIN code: 3114-0517
Nikolay Yu. Sokolov, Cand. Sci. (Med.), Head of the Oncology Department of Antitumor Drug Therapy No. 15, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russia; ОRCID iD: https://orcid.org/0000-0002-0706-9675
Alisa G. Minenkova, Physician, Resident in Surgery, Department of Surgery, Faculty of Surgery, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ОRCID iD: https://orcid.org/0000-0001-6996-2724, AuthorID: 57221414403

Similar Articles